The present invention relates to a process for preparing a (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (S,R)-(2), wherein R.sup.1 represents a monovalent hydrocarbon group having 1 to 6 carbon atoms, and a bold wedged bond represents the absolute configuration, and a (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (R,S)-(3), wherein R.sup.1 is as defined above, a hashed wedged bond represents the absolute configuration, and Ac represents an acetyl group, the process comprising: subjecting a (1RS,2SR)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (RS,SR)-(2), wherein R.sup.1 is as defined above, and a hashed unwedged bond represents a relative configuration, to a kinetic resolution reaction with a lipase in the presence of vinyl acetate to obtain the (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((S,R)-(2)) and the (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((R,S)-(3)). ##STR00001##

The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient, wherein the compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.

The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient, wherein the compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.

There is a compound represented by the following formula (I): ##STR00001##
in which R1 and R2, identical or different, represent a C.sub.2-C.sub.30 alkyl group, a C.sub.2-C.sub.30 alkenyl group, a C.sub.2-C.sub.30 alkynyl group, or a C.sub.2-C.sub.30 alkoxy group, the alkyl, alkenyl, alkynyl, or alkoxy groups being optionally substituted with at least one hydroxy, halogen, amino, C.sub.1-C.sub.8 alkyl, or C.sub.1-C.sub.8 alkoxy group, as a temperature change regulating agent in a thermochromic ink composition. There also are thermochromic pigment microcapsules having a compound of formula (I) according to the disclosure, to ink compositions having such thermochromic pigment microcapsules, and to writing instruments comprising such ink compositions.

There is a compound represented by the following formula (I): ##STR00001##
in which R1 and R2, identical or different, represent a C.sub.2-C.sub.30 alkyl group, a C.sub.2-C.sub.30 alkenyl group, a C.sub.2-C.sub.30 alkynyl group, or a C.sub.2-C.sub.30 alkoxy group, the alkyl, alkenyl, alkynyl, or alkoxy groups being optionally substituted with at least one hydroxy, halogen, amino, C.sub.1-C.sub.8 alkyl, or C.sub.1-C.sub.8 alkoxy group, as a temperature change regulating agent in a thermochromic ink composition. There also are thermochromic pigment microcapsules having a compound of formula (I) according to the disclosure, to ink compositions having such thermochromic pigment microcapsules, and to writing instruments comprising such ink compositions.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((-)-trans-Δ.sup.9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((-)-trans-Δ.sup.9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified by characteristic chemical data and mass spectra of said lipid compounds, said lipid compound in essentially pure form, and an ophthalmic vehicle comprising a therapeutic agent and a compound present in the secretions of the Harderian gland, e.g. a lipid compound, found in the secretions of the Harderian gland, e.g. a rabbit Harderian gland.